Impact of Smoking on the Metabolic Action of Subcutaneous Regular Insulin in Type 2 Diabetic Patients

Abstract

Background and Aims: Smoking has repeatedly been associated with alterations in both insulin sensitivity and insulin absorption in type 2 diabetes, which should lead to differences in the pharmacokinetic (PK) and pharmacodynamic (PD) properties of regular insulin (RI). However, a direct comparison of the PK/PD-effects of RI has never been performed in these patients. Therefore, the aim of this exploratory study was to investigate the time-action profile of RI in a small group of smoking and matching non-smoking patients with type 2 diabetes using the euglycemic glucose clamp technique, which is seen as the gold standard for PD/PK investigations. Material and Methods: Nine smokers (more than 10 cigarettes per day) and nine non-smokers matched for gender, age, and BMI (without significant differences in HbA_1c, diabetes duration or blood pressure) were enrolled in the study. Patients’ blood glucose was stabilized overnight at 7.2 mmol/l using a Biostator. Smokers were required to smoke one cigarette within ninety minutes prior to injection of 18 U RI s. c. in the morning. Glucose infusion rates (GIR) were registered for the subsequent 480 min. Results: Injection of 18 U of RI resulted in significantly higher insulin concentrations in smokers compared to non-smokers, in particular in the later part of the experiment (Insulin-AUC_{240 - 480} 10.5 ± 2.3 (mean ± SD) vs. 7.8 ± 1.6 μU/ml/min, p < 0.05). This was also reflected in the PD results with a higher metabolic effect in smokers in the last four hours of the experiment (GIR-AUC_{240 - 480} 0.9 ± 0.4 vs. 0.6 ± 0.3 g/kg, p < 0.05). Pharmacokinetic analyses revealed a trend towards a lower insulin clearance in smokers (1.1 ± 0.2 vs. 1.4 ± 0.4 l/min, p = 0.08). Conclusions: This pilot study conducted in a small group of patients with type 2 diabetes shows that regular insulin exhibits a longer-lasting rise in insulin concentrations and a higher metabolic effect four to eight hours after injection in smokers compared to non-smokers. This suggests that hyperinsulinemia in smoking type 2 diabetic patients is at least partly caused by a deterioration in insulin clearance.

Key words

Insulin resistance - Smoking - Insulin clearance - Insulin action - Type 2 diabetes

References

• 1 Axelsson T, Jansson P A, Smith U, Eliasson B. Nicotine infusion acutely impairs insulin sensitivity in type 2 diabetic patients but not in healthy subjects.  J Intern Med. 2001;  249 539-544
• 2 Assali A R, Beigel Y, Schreibman R, Shafer Z, Fainaru M. Weight gain and insulin resistance during nicotine replacement therapy.  Clin Cardiol. 1999;  22 357-360
• 3 Eliasson B, Smith U. Leptin levels in smokers and long-term users of nicotine gum.  Eur J Clin Invest. 1999;  29 145-152
• 4 Attvall S, Fowelin J, Lager I, von Schenck H, Smith U. Smoking induces insulin resistance - a potential link with the insulin resistance syndrome.  J Intern Med. 1993;  233 327-332
• 5 Facchini F S, Hollenbeck C B, Jeppesen J, Chen Y D, Reaven G M. Insulin resistance and cigarette smoking.  Lancet. 1992;  339 1128-1130
• 6 Epifano L, Di Vincenzo A, Fanelli C, Porcellati F, Perriello G, De Feo P. et al . Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus.  Eur J Clin Pharmacol. 1992;  43 257-263
• 7 Klemp P, Staberg B, Madsbad S, Kolendorf K. Smoking reduces insulin absorption from subcutaneous tissue.  Br Med J (Clin Res Ed). 1982;  284 237
• 8 Benowitz N L. Drug therapy. Pharmacologic aspects of cigarette smoking and nicotine addition.  N Engl J Med. 1988;  319 1318-1330
• 9 Heinemann L, Richter B. Clinical pharmacology of human insulin.  Diabetes Care. 1993;  16 Suppl 3 90-100
• 10 Gibaldi M. Biopharmaceutics and clinical pharmacokinetics. Philadelphia; Lea and Febiger 1991
• 11 Berne C. Metabolic effects of ACE inhibitors.  J Intern Med Suppl. 1991;  735 119-125
• 12 Heinemann L, Heise T, Ampudia J, Sawicki P T. Einfluss von ACE-Hemmern auf die Insulinsensitivität: eine kritische Übersicht.  Nieren u Hochdruckkrankheiten. 1995;  24 240-245
• 13 Mühlhauser I, Cüppers H J, Berger M. Smoking and insulin absorption from subcutaneous tissue (letter).  BMJ. 1984;  228 1875-1876
• 14 Christiansen J S. Cigarette smoking and prevalence of microangiopathy in juvenile-onset insulin-dependent diabetes mellitus.  Diabetes Care. 1978;  1 146-149
• 15 Sawicki P T. Smoking and diabetic nephropathy. In: Mogensen CE (ed) The kidney and hypertension in diabetes mellitus. Boston, Dordrecht, London; Kluwer Academic Publishers 2000
• 16 Sawicki P T, Didjurgeit U, Muhlhauser I, Bender R, Heinemann L, Berger M. Smoking is associated with progression of diabetic nephropathy.  Diabetes Care. 1994;  17 126-131
• 17 Klein R, Klein B E, Moss S E. The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus.  Arch Intern Med. 1991;  151 1344-1348
• 18 Eliasson B, Taskinen M R, Smith U. Long-term use of nicotine gum is associated with hyperinsulinemia and insulin resistance.  Circulation. 1996;  94 878-881
• 19 Doberne L, Greenfield M S, Schulz B, Reaven G M. Enhanced glucose utilization during prolonged glucose clamp studies.  Diabetes. 1981;  30 829-835
• 20 Chaturvedi N, Stephenson J M, Fuller J H. The relationship between smoking and microvascular complications in the EURODIAB IDDM Complications Study.  Diabetes Care. 1995;  18 785-792
• 21 Lundman B M, Asplund K, Norberg A. Smoking and metabolic control in patients with insulin-dependent diabetes mellitus.  J Intern Med. 1990;  227 101-106
• 22 Helve E, Yki-Jarvinen H, Koivisto V A. Smoking and insulin sensitivity in type I diabetic patients.  Metabolism. 1986;  35 874-877
• 23 Mühlhauser I, Sawicki P, Berger M. Cigarette-smoking as a risk factor for macroproteinuria and proliferative retinopathy in type 1 (insulin-dependent) diabetes.  Diabetologia. 1986;  29 500-502
• 24 Klein R, Klein B E, Davis M D. Is cigarette smoking associated with diabetic retinopathy?.  Am J Epidemiol. 1983;  118 228-238
• 25 Algenstaedt P, Rosenblatt N, Kolb I, Krützelmann A, Schwarzloh B, Böttcher A. et al . A new model of primary human adipocytes reveals reduced early insulin signalling in type 2 diabetes.  Horm Metab Res. 2004;  36 531-537
• 26 Carey P E, Stewart M W, Ashworth L, Taylor R. Effect of insulin therapy on plasma leptin and body weight in patients with Type 2 diabetes.  Horm Metab Res. 2003;  35 372-376
• 27 Nannipieri M, Seghieri G, Catalano C, Prontera T, Baldi S, Ferrannini E. Defective regulation and action of atrial natriuretic peptide in Type 2 diabetes.  Horm Metab Res. 2002;  34 265-270
• 28 Wise S D, Seah E S, Yasuda M, Fisher J, Sathirakul K, Aftring P. Effect of smoking on insulin, insulin clearance & time action profile, following regular insulin (abstract). Abstractbook 17th IDF Congress, Mexico, November 2000. Available at http://www.med.nus.edu.sg/lilly/RI_Endocrine_6. htm (access 5th Nov 2004)